Reuters: Tekmira to produce Ebola treatment for U.S. Dept of Defense
“The U.S. Department of Defense has exercised an option with Canada’s Tekmira Pharmaceuticals Corp. for the company to make 500 courses of its experimental treatment for Ebola, Tekmira said on Thursday. The treatment targets the Ebola-Guinea virus variant, which is responsible for the worst outbreak on record that has hit hardest in Liberia, Sierra Leone, and Guinea. It works by preventing the virus from replicating…” (11/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.